13F Holdings
中文EN

GRFS Grifols SA IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1438569 · Reporting currency EUR

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY9.4%
TTM net income YoY270.8%
TTM EPS YoY283.3%
Revenue 3-yr CAGR13.5%
Net income 3-yr CAGR-6.0%

Margins

Gross margin38.7%
Operating margin16.5%
Net margin2.2%
FCF margin9.3%
EBITDA margin22.6%

Returns

ROE2.8%
ROA0.7%
ROIC (approx.)7.1%
Asset turnover0.34x

Leverage & solvency

Liabilities / assets59.8%
Debt / equity0.45x
Current ratio2.66x
Interest coverage1.67x

Cash quality & payout

Operating cash flow / net income5.75x
Accruals ratio-3.5%
Payout ratio0.6%
Capex / revenue3.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: EUR FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31FY20202020-12-31
Income statement
Revenue7.21B6.59B6.06B4.93B5.34B
Cost of revenue4.42B4.11B3.85B2.97B3.08B
Gross profit2.79B2.48B2.21B1.96B2.26B
R&D expense384.04M395.28M361.14M354.88M294.22M
SG&A expense1.26B1.37B1.20B1.06B985.62M
Operating income1.19B782.32M782.44M595.06M996.13M
Interest expense714.76M596.88M478.32M267.70M249.64M
Pretax income444.00M207.02M338.01M350.45M878.63M
Income tax231.19M43.35M90.11M85.13M169.64M
Net income156.92M42.32M185.03M188.73M618.55M
EBITDA1.63B1.23B1.19B954.83M1.32B
EPS (basic)0.230.060.270.280.90
EPS (diluted)0.230.060.270.280.90
Weighted avg. shares (diluted)679.92M677.10M679.29M681.40M685.14M
Balance sheet
Cash & equivalents979.78M529.58M549.21M2.68B579.65M
Receivables835.60M767.26M739.04M499.71M520.16M
Inventory3.56B3.48B3.24B2.26B2.00B
Current assets5.73B6.13B4.69B5.51B3.16B
PP&E, netmay include right-of-use assets (IFRS)3.34B3.25B3.30B2.55B2.32B
Goodwill7.40B6.80B7.01B6.23B5.33B
Intangibles2.93B2.83B2.95B1.64B1.56B
Total assets21.41B20.99B21.23B19.23B15.27B
Current liabilities2.16B2.33B2.02B3.47B1.34B
Short-term debt318.20M674.31M449.41M127.89M169.56M
Long-term debt2.34B3.65B3.59B3.58B3.30B
Total debt2.66B4.32B4.04B3.71B3.46B
Total liabilities12.80B13.48B13.25B11.92B8.55B
Shareholders' equity5.88B5.37B5.65B5.52B5.11B
Net debt1.68B3.79B3.49B1.03B2.89B
Cash flow statement
Operating cash flow902.17M218.69M-1.43M596.98M1.11B
Capital expenditure232.54M224.44M283.80M247.37M280.15M
Free cash flow669.63M-5.75M-285.23M349.60M830.18M
Investing cash flow886.67M-394.72M-2.00B-854.15M-858.12M
Financing cash flow-1.36B171.49M-164.90M2.30B-354.40M
Depreciation & amortization437.90M446.42M410.98M359.77M321.53M
Dividends paid962,0000592,000258.95M113.23M
Share buybacks—03.46M125.70M—

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.